Supernus Pharmaceuticals, Inc. (SUPN) is in Healthcare, Drug Manufacturers - Specialty & Generic, based in United States, listed on NasdaqGM. Market cap 2.45B USD. 52-week range 40.51 to 59.68 USD. Data as of 2026-10-09.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the ...